Researchers from Japan have shown that benzaldehyde, a compound responsible for the aroma of almonds, halts the growth and spread of therapy-resistant pancreatic cancer.

By preventing various signalling proteins and histone modifiers like Ser28-phosphorylated histone H3 (H3S28ph) from binding to 14-3-3ζ protein, the study has shown that benzaldehyde overcomes therapy resistance and blocks plasticity to prevent the spread of cancer.

The research, published in the British Journal of Cancer, was led by Dr Hideyuki Saya, Director of the Oncology Innovation Center, Fujita Health University, Japan.

Dr Saya said: “In the 1980s, researchers demonstrated the anticancer activity of benzaldehyde and its derivatives. The first author of our study, Dr Jun Saito, is the daughter of one of the researchers involved in those early studies, and she was driven by a strong desire to uncover the mechanism behind benzaldehyde’s anticancer effects.”

Early studies reported the ability of benzaldehyde to inhibit the progressive development of mouse embryonic cells, indicating its potential in preventing rapid cell proliferation. Here, the anticancer effects of benzaldehyde were studied by using a mouse model grafted to have a growing pancreatic cancer.

In cell culture studies, benzaldehyde inhibited the growth of cancer cells resistant to radiation therapy and also those resistant to treatment with osimertinib, an agent blocking tyrosine kinases in growth factor signalling.

The research showed that benzaldehyde prevented 14-3-3ζ-dependent phosphorylation of the serine28 amino acid of histone H3, reducing the expression of genes responsible for treatment resistance.

Treatment of mice with a benzaldehyde derivative inhibited the growth of pancreatic tumours and suppressed the epithelial-to-mesenchymal plasticity, thus preventing the spread of cancer to distant organs like the lungs.

Diana Turner, Senior Digital Content Editor, DDW